Overview

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program in Phase 2 for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP. AnaptysBio’s antibody pipeline has been developed using our proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).

Our most advanced wholly owned antibody programs, imsidolimab, rosnilimab and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.

We are developing our imsidolimab product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory disease called generalized pustular psoriasis (GPP). We plan to outlicense imsidolimab prior to potential FDA approval.

Our second wholly owned program rosnilimab, an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases.

Our third wholly owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro.

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with GlaxoSmithKline (GSK).

Strategy

Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease

We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program; and ANB032, our anti-BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Continuing imsidolimab development in GPP and outlicensing plans

We are advancing imsidolimab, our anti-IL-36R antibody, for the treatment of generalized pustular psoriasis (GPP), and we are planning to outlicense imsidolimab prior to potential FDA approval.

Identifying emerging target biology opportunities in inflammation and expanding our proprietary pipeline by generating new antibody product candidates using our technology platform

We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.

Retaining rights to strategic products in key commercial markets

We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.

Senior Leadership Team

Daniel Faga

Daniel Faga

Interim President & CEO

Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations.

+
Martin Dahl, Ph.D.

Martin Dahl, Ph.D.

Senior Vice President of Research

Martin Dahl, Ph.D. joined AnaptysBio in 2018 and has more than 25 years of experience in drug discovery and research.

+
Paul F. Lizzul, M.D., PH.D., M.P.H, M.B.A.

Paul F. Lizzul, M.D., PH.D., M.P.H, M.B.A.

Chief Medical Officer

Dr. Lizzul joined AnaptysBio in July 2020 and leads the company’s development organization, including clinical medicine, clinical operations, regulatory affairs, pharmacology and toxicology functions.

+
Eric Loumeau

Eric Loumeau

Chief Operating Officer

Eric Loumeau joined AnaptysBio in August 2018 with more than twenty years of experience in biotech.

+
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources

Beth Mueller joined AnaptysBio in October 2019 with over 20 years of experience in all aspects of human resources, including organizational development, talent acquisition, and compensation in the biotechnology industry.

+
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer

Dennis Mulroy joined AnaptysBio in July 2020 after serving as Chief Financial Officer of La Jolla Pharmaceutical Company

+
Ben Stone

Ben Stone

Senior Vice President, Corporate Development

Ben Stone joined AnaptysBio in May 2022 to lead the company’s Corporate Development functions.

+
Stephen Parmley, Ph.D.

Stephen Parmley, Ph.D.

Vice President, Target Biology

Stephen Parmley joined AnaptysBio in November of 2015 with more than 30 years of experience in protein engineering, immunology and project leadership.

+

Board Of Directors

Daniel Faga

Interim President & CEO

Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

Laura J. Hamill

Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences

Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions.

+

Magda Marquet, Ph.D.

Co-founder of Althea Technologies, AltheaDx and ALMA Life Sciences, LLC

Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors.

+

Oleg Nodelman

Founder and Portfolio Manager of EcoR1 Capital LLC

Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing.

+

Hollings Renton

Former President and CEO of Onyx Pharmaceuticals

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.

+

John Schmid

Former CFO of Auspex Pharmaceuticals

John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer.

+

James N. Topper, M.D., Ph.D.

Chairman of AnaptysBio
Managing General Partner at Frazier Healthcare

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Scientific Advisory Board

Michael Gallatin, Ph.D.

Former Vice President and Scientific Director of ICOS Corporation

Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).

+

Christopher Hunter, Ph.D.

Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine

Christopher Hunter, Ph.D. is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]

+

John G. Monroe, Ph.D.

Emeritus Professor, University of Pennsylvania School of Medicine

John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.

+

Contact

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801

 

Phone: (858) 362-6295
Fax: (858) 362-6296
info@anaptysbio.com

General Information

info@anaptysbio.com

Job Opportunities

Please see our Job Openings page.